Comparison of angiogenesis-related factor expression in primary tumor cultures under normal and hypoxic growth conditions

被引:15
作者
Heinzman, Jamie M. [1 ]
Brower, Stacey L. [1 ]
Bush, Jason E. [1 ]
机构
[1] Precis Therapeut Inc, Res & Dev, Pittsburgh, PA USA
关键词
Vascular Endothelial Growth Factor; Hypoxic Condition; Vascular Endothelial Growth Factor Expression; Normoxic Condition; Hypoxic Environment;
D O I
10.1186/1475-2867-8-11
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A localized hypoxic environment occurs during tumor growth necessitating an angiogenic response or tumor necrosis results. Novel cancer treatment strategies take advantage of tumor-induced vascularisation by combining standard chemotherapeutic agents with angiogenesis-inhibiting agents. This has extended the progression-free interval and prolonged survival in patients with various types of cancer. We postulated that the expression levels of angiogenesis-related proteins from various primary tumor cultures would be greater under hypoxic conditions than under normoxia. Methods: Fifty cell sources, including both immortalized cell lines and primary carcinoma cells, were incubated under normoxic conditions for 48 hours. Then, cells were either transferred to a hypoxic environment (1% O-2) or maintained at normoxic conditions for an additional 48 hours. Cell culture media from both conditions was collected and analyzed via an ELISA-based assay to determine expression levels of 11 angiogenesis-related factors: VEGF, PDGF-AA, PDGF-AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-beta 1, TGF-beta 2, and TGF-beta 3. Results: A linear correlation between normoxic and hypoxic growth conditions exists for expression levels of eight of eleven angiogenesis-related proteins tested including: VEGF, IL-8, PDGF-AA, PDGF-AA/BB, TGF-beta 1, TGF-beta 2, EGF, and IP-10. For VEGF, the target of current therapies, this correlation between hypoxia and higher cytokine levels was greater in primary breast and lung carcinoma cells than in ovarian carcinoma cells or tumor cell lines. Of interest, patient cell isolates differed in the precise pattern of elevated cytokines. Conclusion: As linear correlations exist between expression levels of angiogenic factors under normoxic and hypoxic conditions in vitro, we propose that explanted primary cells may be used to probe the in vivo hypoxic environment. Furthermore, differential expression levels for each sample across all proteins examined suggests it may be possible to build a predictor for angiogenesis-related anticancer agents, as each sample has a unique expression profile. Further studies should be performed to correlate in vitro protein expression levels of angiogenesis-related factors with in vivo patient response.
引用
收藏
页数:9
相关论文
共 29 条
[1]   Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression [J].
Brogi, E ;
Schatteman, G ;
Wu, T ;
Kim, EA ;
Varticovski, L ;
Keyt, B ;
Isner, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (02) :469-476
[2]  
Cheng M, 2007, CYTOKINE IN PRESS
[3]  
De Luca A, 2007, J CELL PHYS IN PRESS
[4]   Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay [J].
Gallion, H ;
Christopherson, WA ;
Coleman, RL ;
Demars, L ;
Herzog, T ;
Hosford, S ;
Schellhas, H ;
Wells, A ;
Sevin, BU .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) :194-201
[5]  
Harada S, 2007, INT J ONCOL, V30, P1461
[6]   Ex vivo enrichment of malignant carcinoma cells in primary culture [J].
Heinzman, Jamie M. ;
Brower, Stacey L. ;
Bush, Jason E. ;
Silverman, Jan F. .
PATHOLOGY, 2007, 39 (05) :491-494
[7]   Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J].
Hicklin, DJ ;
Ellis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1011-1027
[8]   Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects [J].
Höckel, M ;
Vaupel, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :266-276
[9]   Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor [J].
Ignoffo, RJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (21) :S21-S26
[10]  
Kenny PA, 2005, INT J CANCER, P168